Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Kinase Biomarkers Are Active in Basal Breast Cancer

By LabMedica International staff writers
Posted on 21 Oct 2010
A protein screening technology has been used to profile basal breast cancer, a particularly aggressive sub-type of breast cancer, identifying specific targets for future treatments. More...


Basal breast cancers display a characteristic "signature” or "fingerprint” of tyrosine phosphorylation, or phosphate molecules attaching to the tyrosine amino acids within proteins. These characteristics can be ascertained by various methods including Phosphopeptide immunoprecipitation, phosphorylation assays with tyrosine kinase inhibitors, and cellular proliferation assays.

Scientists at the Garvan Institute of Medical Research (Sydney, Australia), subjected cancer cells to mass spectrometry-based profiling of protein tyrosine phosphorylation events. They have focused in particular on a process known as phosphorylation, a way in which proteins modify each other's behavior by exchanging phosphate molecules. In addition, rather than looking at proteins one at a time, they have used a technology that allows the investigator to examine the phosphorylation of all cellular proteins.

Their findings show that basal breast cancers display a tyrosine phosphorylation signature and these cancers show heightened activity of several different kinds of cell-signaling proteins known as kinases. Kinases are responsible for attaching the phosphate groups to proteins. Each cancer type has a submicroscopic fingerprint defined by its proteins and until now, basal breast cancer's protein fingerprint had remained elusive. These studies highlight multiple kinases and substrates for further evaluation as therapeutic targets and biomarkers. However, they also indicate that patient stratification based on expression/activation of drug targets, coupled with use of multi-kinase inhibitors or combination therapies may be required for effective treatment of this breast cancer subgroup. Basal breast cancers represent between 10 and 27% of all breast cancers, depending on the population sampled. They lack estrogen and progesterone receptors, so are resistant to hormone therapies such as tamoxifen. They are also resistant to Herceptin, a monoclonal antibody effective in treating a different subset of breast cancers.

Falko Hochgräfe, Ph.D., the senior author of the study, said, "Our findings suggest that it would be a good idea to stratify patients according to which signaling proteins, or kinases, were found in their cancers. These kinases can then be targeted by specific therapies, and because several kinases are commonly activated in basal breast cancers, use of combination therapies that target more than one kinase, or multi-kinase inhibitors, is likely to more effective in the clinic" The study was published online in October 2010, in Cancer Research.

Related Links:
Garvan Institute of Medical Research





Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.